Evaluation of Efflux-Mediated Resistance and Biofilm Formation in Virulent Associated with Healthcare Infections
Overview
Authors
Affiliations
is a significant pathogen identified with healthcare-associated infections. The present study evaluates the role of biofilm and efflux pump activities in influencing high-level resistance in virulent strains in clinical infection. Phenotypic resistance in biotyped ( = 147) from diagnosed disease conditions was classified based on multiple antibiotic resistance (MAR) indices and analysed with logistic regression for risk factors. Efflux pump activity, biofilm formation, and virulence factors were analysed for optimal association in infection using receiver operation characteristics (ROC). Age-specificity (OR [CI] = 0.986 [0.946-1.027]), gender (OR [CI] = 1.44 [0.211-9.827]) and infection sources (OR [CI] = 0.860 [0.438-1.688]) were risk variables for multidrug resistance (MDR)- infection ( < 0.05). Biofilm formers caused 48.2% and 18.5% otorrhea and wound infections (95% CI = 0.820-1.032; = 0.001) respectively and more than 30% multidrug resistance (MDR) strains demonstrated high-level efflux pump activity (95% CI = 0.762-1.016; = 0.001), protease (95% CI = 0.112-0.480; = 0.003), lipase (95% CI = 0.143-0.523; = 0.001), and hemolysin (95% CI = 1.109-1.780; = 0.001). Resistance relatedness of more than 80% and 60% to cell wall biosynthesis inhibitors (ceftazidime, ceffproxil, augumentin, ampicillin) and, DNA translational and transcriptional inhibitors (gentamicin, ciprofloxacin, ofloxacin, nitrofurantoin) were observed ( < 0.05). Strong efflux correlation (r = 0.85, = 0.034) with MDR strains, with high predictive performances in efflux pump activity (ROC-AUC 0.78), biofilm formation (ROC-AUC 0.520), and virulence hierarchical-clustering. Combine activities of the expressed efflux pump and biofilm formation in MDR- pose risk to clinical management and infection control.
Fecal Carriage of Colibactin-Encoding Associated With Colorectal Cancer Among a Student Populace.
Akinduti P, Izevbigie O, Akinduti O, Enwose E, Amoo E Open Forum Infect Dis. 2024; 11(4):ofae106.
PMID: 38560611 PMC: 10981395. DOI: 10.1093/ofid/ofae106.
Soontarach R, Srimanote P, Voravuthikunchai S, Chusri S Pharmaceuticals (Basel). 2024; 17(2).
PMID: 38399370 PMC: 10893532. DOI: 10.3390/ph17020155.
Impact of Extract on Biofilm Formation for ESBL-: An Model Study.
Abdulkareem A, Alalwani A, Ahmed M, Al-Meani S, Al-Janaby M, Al-Qaysi A Pharmaceuticals (Basel). 2023; 16(10).
PMID: 37895854 PMC: 10609828. DOI: 10.3390/ph16101383.
Ammar Y, Ragab A, Migahed M, Al-Sharbasy S, Salem M, Riad O RSC Adv. 2023; 13(39):27363-27384.
PMID: 37711372 PMC: 10498153. DOI: 10.1039/d3ra04230h.
Avakh A, Grant G, Cheesman M, Kalkundri T, Hall S Antibiotics (Basel). 2023; 12(8).
PMID: 37627724 PMC: 10451789. DOI: 10.3390/antibiotics12081304.